Search tips
Search criteria 


Logo of aacPermissionsJournals.ASM.orgJournalAAC ArticleJournal InfoAuthorsReviewers
Antimicrob Agents Chemother. 1997 July; 41(7): 1455–1459.
PMCID: PMC163939

Efficacy of D0870 treatment of experimental Candida vaginitis.


In this study, oral administration of the triazole D0870 was compared to oral administration of fluconazole in the treatment of experimental vaginal candidiasis. With an estrogen-dependent murine model of Candida albicans vaginal infection, the effects of D0870 on several isolates, including fluconazole-susceptible and -resistant isolates, were tested. D0870, at doses of 0.5 and 2.5 mg/kg of body weight given once over the course of a 10-day infection, was effective in eradicating vaginitis caused by fluconazole-susceptible laboratory and clinical isolates, respectively. In contrast, a stricter treatment regimen (every 24 to 48 h) with 10 and 25 mg of fluconazole per kg was required to achieve similar reductions in vaginal fungal titers induced by the same isolates. Whereas fluconazole was consistently ineffective in infections induced by fluconazole-resistant isolates, as predicted by in vitro susceptibility tests, D0870 was effective, although a daily regimen of 25 mg/kg was required. Additional studies showed that despite the in vitro activity of D0870 against two clinical Candida glabrata isolates, neither D0870 nor fluconazole was effective at daily doses as high as 100 and 125 mg/kg, respectively. Taken together, although D0870 failed to show efficacy against experimental C. glabrata vaginitis, D0870 was superior to fluconazole in the treatment of experimental C. albicans vaginitis caused by isolates that were either susceptible or resistant to fluconazole.

Full Text

The Full Text of this article is available as a PDF (128K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Arilla MC, Carbonero JL, Schneider J, Regúlez P, Quindós G, Pontón J, Cisterna R. Vulvovaginal candidiasis refractory to treatment with fluconazole. Eur J Obstet Gynecol Reprod Biol. 1992 Mar 23;44(1):77–80. [PubMed]
  • Bart-Delabesse E, Boiron P, Carlotti A, Dupont B. Candida albicans genotyping in studies with patients with AIDS developing resistance to fluconazole. J Clin Microbiol. 1993 Nov;31(11):2933–2937. [PMC free article] [PubMed]
  • Case CP, MacGowan AP, Brown NM, Reeves DS, Whitehead P, Felmingham D. Prophylactic oral fluconazole and candida fungaemia. Lancet. 1991 Mar 30;337(8744):790–790. [PubMed]
  • Clemons KV, Hanson LH, Stevens DA. Activities of the triazole D0870 in vitro and against murine blastomycosis. Antimicrob Agents Chemother. 1993 May;37(5):1177–1179. [PMC free article] [PubMed]
  • Clemons KV, Stevens DA. Utility of the triazole D0870 in the treatment of experimental systemic coccidioidomycosis. J Med Vet Mycol. 1994;32(4):323–326. [PubMed]
  • Clemons KV, Stevens DA. Efficacy of the triazole D0870 in a murine model of systemic histoplasmosis. Antimicrob Agents Chemother. 1995 Mar;39(3):778–780. [PMC free article] [PubMed]
  • Clift RA. Candidiasis in the transplant patient. Am J Med. 1984 Oct 30;77(4D):34–38. [PubMed]
  • Correa AL, Velez G, Albert M, Luther M, Rinaldi MG, Graybill JR. Comparison of D0870 and fluconazole in the treatment of murine cryptococcal meningitis. J Med Vet Mycol. 1995 Nov-Dec;33(6):367–374. [PubMed]
  • Dunn PL, North RJ. Resolution of primary murine listeriosis and acquired resistance to lethal secondary infection can be mediated predominantly by Thy-1+ CD4- CD8- cells. J Infect Dis. 1991 Nov;164(5):869–877. [PubMed]
  • Fan-Havard P, Capano D, Smith SM, Mangia A, Eng RH. Development of resistance in candida isolates from patients receiving prolonged antifungal therapy. Antimicrob Agents Chemother. 1991 Nov;35(11):2302–2305. [PMC free article] [PubMed]
  • Fidel PL, Jr, Lynch ME, Sobel JD. Candida-specific cell-mediated immunity is demonstrable in mice with experimental vaginal candidiasis. Infect Immun. 1993 May;61(5):1990–1995. [PMC free article] [PubMed]
  • Fidel PL, Jr, Cutright JL, Tait L, Sobel JD. A murine model of Candida glabrata vaginitis. J Infect Dis. 1996 Feb;173(2):425–431. [PubMed]
  • Fidel PL, Jr, Lynch ME, Sobel JD. Candida-specific Th1-type responsiveness in mice with experimental vaginal candidiasis. Infect Immun. 1993 Oct;61(10):4202–4207. [PMC free article] [PubMed]
  • Fleury FJ. Adult vaginitis. Clin Obstet Gynecol. 1981 Jun;24(2):407–438. [PubMed]
  • Geiger AM, Foxman B, Sobel JD. Chronic vulvovaginal candidiasis: characteristics of women with Candida albicans, C glabrata and no candida. Genitourin Med. 1995 Oct;71(5):304–307. [PMC free article] [PubMed]
  • Graybill JR, Najvar LK, Holmberg JD, Luther MF. Fluconazole, D0870, and flucytosine treatment of disseminated Candida tropicalis infections in mice. Antimicrob Agents Chemother. 1995 Apr;39(4):924–929. [PMC free article] [PubMed]
  • Humphrey MJ, Jevons S, Tarbit MH. Pharmacokinetic evaluation of UK-49,858, a metabolically stable triazole antifungal drug, in animals and humans. Antimicrob Agents Chemother. 1985 Nov;28(5):648–653. [PMC free article] [PubMed]
  • Karabinis A, Hill C, Leclercq B, Tancrède C, Baume D, Andremont A. Risk factors for candidemia in cancer patients: a case-control study. J Clin Microbiol. 1988 Mar;26(3):429–432. [PMC free article] [PubMed]
  • Karyotakis NC, Dignani MC, Hachem R, Anaissie EJ. Activities of D0870, a novel triazole, against Candida lusitaniae and Trichosporon beigelii in experimental murine infections. Antimicrob Agents Chemother. 1995 Feb;39(2):571–573. [PMC free article] [PubMed]
  • Klein RS, Harris CA, Small CB, Moll B, Lesser M, Friedland GH. Oral candidiasis in high-risk patients as the initial manifestation of the acquired immunodeficiency syndrome. N Engl J Med. 1984 Aug 9;311(6):354–358. [PubMed]
  • Lynch ME, Sobel JD, Fidel PL., Jr Role of antifungal drug resistance in the pathogenesis of recurrent vulvovaginal candidiasis. J Med Vet Mycol. 1996 Sep-Oct;34(5):337–339. [PubMed]
  • Macher AM. The pathology of AIDS. Public Health Rep. 1988 May-Jun;103(3):246–254. [PMC free article] [PubMed]
  • Pfaller MA, Bale MJ, Buschelman B, Rhomberg P. Antifungal activity of a new triazole, D0870, compared with four other antifungal agents tested against clinical isolates of Candida and Torulopsis glabrata. Diagn Microbiol Infect Dis. 1994 Jun;19(2):75–80. [PubMed]
  • Redondo-Lopez V, Lynch M, Schmitt C, Cook R, Sobel JD. Torulopsis glabrata vaginitis: clinical aspects and susceptibility to antifungal agents. Obstet Gynecol. 1990 Oct;76(4):651–655. [PubMed]
  • Ruhnke M, Eigler A, Engelmann E, Geiseler B, Trautmann M. Correlation between antifungal susceptibility testing of Candida isolates from patients with HIV infection and clinical results after treatment with fluconazole. Infection. 1994 Mar-Apr;22(2):132–136. [PubMed]
  • Saag MS, Dismukes WE. Azole antifungal agents: emphasis on new triazoles. Antimicrob Agents Chemother. 1988 Jan;32(1):1–8. [PMC free article] [PubMed]
  • Sandven P, Bjørneklett A, Maeland A. Susceptibilities of Norwegian Candida albicans strains to fluconazole: emergence of resistance. The Norwegian Yeast Study Group. Antimicrob Agents Chemother. 1993 Nov;37(11):2443–2448. [PMC free article] [PubMed]
  • Sangeorzan JA, Bradley SF, He X, Zarins LT, Ridenour GL, Tiballi RN, Kauffman CA. Epidemiology of oral candidiasis in HIV-infected patients: colonization, infection, treatment, and emergence of fluconazole resistance. Am J Med. 1994 Oct;97(4):339–346. [PubMed]
  • Sobel JD. Management of recurrent vulvovaginal candidiasis with intermittent ketoconazole prophylaxis. Obstet Gynecol. 1985 Mar;65(3):435–440. [PubMed]
  • Sobel JD. Pathogenesis and epidemiology of vulvovaginal candidiasis. Ann N Y Acad Sci. 1988;544:547–557. [PubMed]
  • Sobel JD, Vazquez JA. Symptomatic vulvovaginitis due to fluconazole-resistant Candida albicans in a female who was not infected with human immunodeficiency virus. Clin Infect Dis. 1996 Apr;22(4):726–727. [PubMed]
  • Wardle HM, Law D, Moore CB, Mason C, Denning DW. In vitro activity of D0870 compared with those of other azoles against fluconazole-resistant Candida spp. Antimicrob Agents Chemother. 1995 Apr;39(4):868–871. [PMC free article] [PubMed]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)